PALO ALTO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a new class of allergy therapeutics, today announced its launch with a $70 million Series A ...

A GIF showing a protein mimicking IL-2 binding to IL-2 receptors, then changing shape in response to an effector molecule, which forces it off of one of the receptors. A protein mimicking IL-2 called ...

ICANS remains a frequent and unpredictable toxicity, affecting approximately half of patients receiving CAR-T therapy, Approximately half of patients undergoing chimeric antigen receptor T-cell (CAR-T ...

An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors. This is an ASCO Meeting ...

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...

B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy demonstrated safety in patients with multiple myeloma (MM) and central nervous system (CNS) involvement, achieving an ...

Plant intracellular nucleotide-binding and leucine-rich repeat immune receptors (NLRs) play a key role in activating a strong pathogen defense response. Plant NLR proteins are tightly regulated and ...

– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – The ...

Scientists at UW Medicine, University of Washington, and their collaborators have pinpointed exactly when cytotoxic T lymphocytes form memories during infection. They also examined the epigenetic ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. If you step out of a cool building into a hot and sunny day, you ...